126 related articles for article (PubMed ID: 17164590)
1. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.
Dilhuydy MS; Durieux A; Pariente A; de Clermont H; Pasticier G; Monteil J; Ravaud A
Oncology; 2006; 70(5):339-44. PubMed ID: 17164590
[TBL] [Abstract][Full Text] [Related]
2. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
[TBL] [Abstract][Full Text] [Related]
3. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
[TBL] [Abstract][Full Text] [Related]
4. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
5. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.
Jadvar H; Kherbache HM; Pinski JK; Conti PS
Clin Nephrol; 2003 Dec; 60(6):395-400. PubMed ID: 14690256
[TBL] [Abstract][Full Text] [Related]
7. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K
Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging renal cell carcinoma.
Ozturk H
Minerva Urol Nefrol; 2016 Jun; 68(3):263-9. PubMed ID: 25916217
[TBL] [Abstract][Full Text] [Related]
9. Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
Harrison MR; George DJ
Clin Cancer Res; 2011 Sep; 17(18):5841-3. PubMed ID: 21926167
[TBL] [Abstract][Full Text] [Related]
10. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
11. Sarcomatoid renal cell carcinoma: rapid dissemination detected on FDG PET-CT.
Thambugala GM; Mohamed A; O' Neill GF; Fulham MJ
Australas Radiol; 2006 Dec; 50(6):604-6. PubMed ID: 17107535
[TBL] [Abstract][Full Text] [Related]
12. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma.
Rodríguez Martínez de Llano S; Jiménez-Vicioso A; Mahmood S; Carreras-Delgado JL
Rev Esp Med Nucl; 2010; 29(1):12-9. PubMed ID: 20022140
[TBL] [Abstract][Full Text] [Related]
14. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of PET/CT 18-FDG for the diagnosis and follow-up of urological, urothelial and kidney tumours.
González-Ruiz de León C; García-Rodríguez J; Pérez-Castro N; Vigil-Díaz C; Pérez-Haro ML; Fernández-Gómez JM
Actas Urol Esp (Engl Ed); 2019; 43(1):32-38. PubMed ID: 30100141
[TBL] [Abstract][Full Text] [Related]
16. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors].
Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M
Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099
[TBL] [Abstract][Full Text] [Related]
17. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
[TBL] [Abstract][Full Text] [Related]
18. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
19. Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma?
Mennitto A; Grassi P; Verzoni E; Ratta R; Procopio G
J Med Imaging Radiat Oncol; 2017 Apr; 61(2):250-251. PubMed ID: 28070961
[No Abstract] [Full Text] [Related]
20. [Positron emission tomography in diagnosis of renal cell carcinoma].
Bachor R; Kotzerke J; Gottfried HW; Brändle E; Reske SN; Hautmann R
Urologe A; 1996 Mar; 35(2):146-50. PubMed ID: 8650849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
